Compare Boston Scientific Corporation (BSX) vs Global Payments Inc (GPN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Global Payments Inc — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while Global Payments Inc trades at $76.2 (market cap $20.76B). The key difference: Boston Scientific Corporation is far larger — about 3.2× Global Payments Inc's market cap, and Global Payments Inc pays a 1.32% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | GPN | |
|---|---|---|
Market Cap | $66.37B | $20.76B |
Sector | Health | Industrials |
52-Week High | $108.14 | $90.01 |
52-Week Low | $42.63 | $62.47 |
Enterprise Value | $75.94B | $38.48B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
GPN trades at $76.85, up 1.07% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q1 2026 EPS of $2.96, exceeding expectations, and maintains strong cash flow from operations at $2.66B in 2025. However, net income margin turned negative at -7.97% for 2026, reflecting profitability challenges amid rising debt levels, with debt-to-asset ratio increasing to 41.57% in 2025.
The outlook is mixed: analyst consensus is bullish with a $81.56 price target and 58% buy ratings, supported by AI-driven POS expansions and the Worldpay integration. Key risks include margin pressure from fintech competition and high leverage, which could constrain equity returns if revenue growth falters.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →
